Founded in Valhalla, United States, Oligomerix is a biotechnology company dedicated to developing disease-modifying therapeutics for Alzheimer’s disease and related dementias. The company's core mission is to target tau self-association to halt the progression of these neurodegenerative diseases. Oligomerix's drug discovery platform has identified a pipeline of novel small molecule inhibitors, including their lead candidate OLX07010, aimed at treating both common and rare tauopathies.
Oligomerix has garnered attention through its innovative approach and has published significant preclinical data supporting its therapeutic strategies. The company collaborates with various scientific advisory boards and partners to advance its research. Notable achievements include securing patents for their technology and progressing their lead candidate through preclinical stages. Oligomerix's impact lies in its potential to revolutionize the treatment landscape for Alzheimer's and other tau-related diseases.
